Lectin Complement Pathway: Role in Host Defense and Inflammation

The lectin complement pathway is one of three activation routes in the complement system, a network of blood proteins that forms a first line of immune defense. Its core job is to recognize sugar-rich molecular patterns on the surface of bacteria, viruses, fungi, and damaged host cells, then trigger a chain of protein-splitting reactions that tag invaders for destruction, punch holes in their membranes, and recruit immune cells. But this same destructive machinery can misfire, contributing to tissue injury after a heart attack, kidney damage in chronic disease, and runaway inflammation in sepsis. Understanding how the lectin pathway both protects and harms has become increasingly important as drugs designed to block it enter clinical trials.

How the Pathway Spots Invaders

The lectin pathway starts with a set of soluble proteins that patrol the bloodstream looking for foreign sugar structures. These proteins are called pattern recognition molecules, and the best known is mannose-binding lectin, or MBL. MBL has a bouquet-like shape with multiple sugar-binding heads, each of which latches onto arrangements of mannose and other sugars that decorate many bacterial and fungal surfaces but are uncommon on healthy human cells. Alongside MBL, the pathway uses other recognition molecules, including ficolins and collectins, which bind to acetylated sugars and other distinctive patterns.¹ Each of these recognition molecules circulates in complexes with enzymes called MBL-associated serine proteases, or MASPs, which are the actual executors of the cascade.²

One of the more recently studied recognition molecules, collectin-11 (CL-11), has drawn attention for its role in lung defense. Research on SARS-CoV-2, the virus behind COVID-19, showed that CL-11 binds to the spike protein on the virus in a calcium-dependent manner, with binding concentrated on a region called the N-terminal domain rather than the receptor-binding domain the virus uses to enter cells.³ This finding illustrates how the lectin pathway’s repertoire of recognition molecules extends well beyond MBL alone, allowing it to detect a wide range of threats.

From Recognition to a Lethal Cascade

Once a recognition molecule locks onto a target surface, the MASPs it carries spring into action. The sequence depends heavily on two enzymes: MASP-1 and MASP-2. For years researchers assumed MASP-2 could activate itself, but work in human serum showed that MASP-2 activation strictly depends on MASP-1. MASP-1 acts first, activating MASP-2 and also directly contributing about 60% of the protein cleavage needed to assemble the next key complex.⁴ MASP-2 then cleaves two complement proteins, C4 and C2, to produce fragments that assemble into a molecular machine called the C3 convertase on the pathogen surface.⁵ The C3 convertase then cleaves vast quantities of C3, the most abundant complement protein, generating fragments that coat the invader (opsonization), attract immune cells (inflammation), and feed into the terminal pathway that forms membrane-attack complexes to lyse targets directly.

A Backup Route When Components Are Missing

One of the more surprising discoveries about the lectin pathway is that it does not completely shut down when its standard components are absent. Even when C4 is missing, MBL can still support the deposition of C3 fragments on bacterial surfaces, bypassing the normal C3 convertase entirely.⁶ Further work demonstrated that MASP-2 itself can directly cleave native C3 into its active fragments without needing C4 or C2 at all, providing a residual but functionally important activation route.⁷

This bypass matters in real infections. Experiments with the bacterium Streptococcus pneumoniae showed that in C4-deficient serum, roughly half the normal amount of C3 still ended up deposited on the bacterial surface, and this deposition was absent when MASP-2 was also knocked out, confirming it was the lectin pathway’s bypass route rather than the alternative pathway doing the work.⁸ The existence of this fallback mechanism suggests the lectin pathway evolved under strong selective pressure to remain functional even when individual components are deficient, a situation that is actually common in human populations.

Defending Against Bacteria, Viruses, and Fungi

The lectin pathway’s antimicrobial reach is broad. MBL binds to a range of clinically relevant bacteria, and when it does so, it activates C4 deposition on the bacterial surface, flagging the organism for engulfment and destruction by immune cells through a process called opsonophagocytosis.⁹ Against Streptococcus pneumoniae specifically, the lectin pathway has been identified as a critical component of the innate immune response, with mice lacking ficolin showing increased susceptibility to pneumococcal infection.²

Viral defense follows a slightly different mechanism. Early work on influenza demonstrated that a serum mannose-binding lectin could neutralize the virus, but only with complement activation, representing what the researchers described as a previously unrecognized mechanism of complement-dependent viral inactivation that could be important in first-line defense against enveloped viruses.¹⁰ In other words, MBL does not just stick to the virus and block entry on its own; it needs to fire up the complement cascade to truly neutralize the threat.

Fungal defense adds another dimension. MBL binds Candida albicans through its sugar-binding domain, causing the fungal cells to clump together as they transition from yeast to their more invasive hyphal form. This agglutination, combined with enhanced complement activation, inhibited fungal growth even without the direct involvement of phagocytic cells.¹¹ MBL, in this case, acts almost like a molecular net, trapping and restraining the fungus while complement fragments pile on.

Tissue Damage After Blood Flow Is Restored

When a heart attack or stroke cuts off blood flow to tissue and the flow is then restored, the returning blood triggers a wave of complement-mediated injury known as ischemia-reperfusion damage. The lectin pathway plays a surprisingly central role in this process. During oxygen deprivation, cells display altered surface molecules that lectin pathway recognition molecules bind to, essentially treating the body’s own stressed tissue as a target.

In a rat model of heart attack, blocking MBL with a specific antibody before restoring blood flow reduced infarct size by about 39%, cut the loss of the heart enzyme creatine kinase by roughly 48%, and decreased the infiltration of inflammatory white blood cells by around 47%. The treatment also dialed down the expression of inflammatory signaling molecules in the heart tissue.¹² These are striking numbers, and they made the lectin pathway an early candidate for therapeutic intervention in cardiovascular emergencies.

IgA Nephropathy and the Kidneys

IgA nephropathy is the most common form of primary glomerulonephritis worldwide, and the lectin pathway has emerged as a key mediator of kidney injury in this disease. The basic problem is that abnormal IgA antibodies deposit in the kidney’s filtering units, the glomeruli. In up to half of patients, MBL is deposited alongside the IgA, and the presence of lectin pathway recognition molecules in these deposits is associated with more severe glomerular damage and heavier protein loss in the urine.¹³

Biopsy studies have provided more detail. Glomerular deposition of both MBL and L-ficolin was linked to increased mesangial cell proliferation, scarring, and infiltration of inflammatory cells in the kidney, along with significantly more proteinuria.¹⁴ The picture that emerges is that abnormal IgA deposits acquire sugar structures that lectin pathway molecules recognize, leading to local complement activation within the kidney that amplifies inflammation and drives progressive damage.¹⁵

Crosstalk with Blood Clotting and Bradykinin

The lectin pathway does not operate in isolation. Its enzymes spill over into other defense systems in ways that researchers have only recently begun to map. MASP-1 and MASP-2, the same proteases that drive complement activation, can cleave coagulation factors including prothrombin, fibrinogen, and factor XIII. MASP-1 in particular has been shown to activate prothrombin by cutting it at specific sites, generating an alternative active form of thrombin and linking lectin pathway activation directly to clot formation.¹⁶ Animal studies have confirmed that MASP-1 participates in clot formation in living organisms, not just in test tubes.¹⁷

The kinin system, which produces the potent inflammatory mediator bradykinin, is another partner. MASP-1 cleaves high-molecular-weight kininogen in a manner similar to plasma kallikrein and releases bradykinin in the process, establishing a factor XII-independent mechanism for bradykinin generation. Because MBL can bind to endothelial cells under oxidative stress and activate the MASPs locally on the vessel wall, the local concentration of these enzymes can be far higher than in the general circulation, potentially driving intense local inflammation.¹⁸ This web of interactions means that a single lectin pathway activation event can simultaneously trigger complement attack, promote clotting, and generate pain- and swelling-inducing bradykinin, a phenomenon sometimes captured by the umbrella term “thromboinflammation.”

The Double Edge in Sepsis

Sepsis illustrates the lectin pathway’s dual nature at its most extreme. In early infection, MBL and its associated MASPs help clear bacteria and recruit immune cells. But if the infection spirals out of control, unrestrained complement activation feeds into the same coagulation and inflammatory cascades described above, contributing to a systemic thromboinflammatory state that can lead to multiple-organ failure.¹⁹ An excess of MBL-driven activation can itself become harmful through an unbalanced proinflammatory response that inflicts additional injury on the host.²⁰ The practical challenge in treating sepsis is that you cannot simply shut down complement without also weakening the antimicrobial response, and turning it up further risks worsening organ damage. The timing and degree of intervention matter enormously.

Clearing Dead Cells and the Link to Autoimmunity

Beyond fighting pathogens, the lectin pathway serves a housekeeping role. MBL binds to apoptotic cells, the body’s routine cellular debris, and facilitates their removal. Mice engineered to lack MBL showed measurable defects in clearing dying cells. Interestingly, though, these mice did not develop spontaneous autoimmunity or the lymph-node enlargement typically seen when apoptotic cell clearance fails, although they did accumulate increased numbers of a particular type of B cell in the abdomen.²¹ This dissociation between clearance failure and autoimmunity was somewhat unexpected, because the prevailing theory at the time was that poor cleanup of dead cells almost inevitably triggers autoimmune responses. It suggests that redundant systems can compensate for MBL’s absence in preventing self-reactivity, even if they cannot fully replace its debris-clearing function.

In systemic lupus erythematosus, however, the lectin pathway’s engagement with dying cells takes on a different character. Pattern recognition molecules of the lectin pathway can detect damage-associated molecular patterns on apoptotic cells, initiating complement activation. The resulting inflammatory fragments and membrane-attack complexes can contribute directly to tissue injury, and circulating levels of these molecules tend to track with disease activity.²² The difference between helpful cleanup and harmful inflammation seems to depend on context: how much debris there is, how intensely complement is activated, and whether regulatory mechanisms are keeping the response proportional.

Drugs That Block MASP-2

The recognition that the lectin pathway drives injury in specific diseases has led to targeted drug development. The most advanced candidate is narsoplimab, a monoclonal antibody that selectively blocks MASP-2, the enzyme that sits at the chokepoint of the lectin pathway cascade. By inhibiting MASP-2, narsoplimab prevents the lectin pathway from generating complement fragments and membrane-attack complexes while leaving the classical and alternative pathways intact.²³

In a clinical trial for transplant-associated thrombotic microangiopathy, a condition in which lectin pathway activation damages small blood vessels after stem-cell transplantation, weekly narsoplimab infusions produced a response rate of about 61%, with improvement in organ function in roughly three-quarters of patients. One-hundred-day survival after diagnosis was 68% in the full study population and 94% among those who responded to treatment.²⁴ In a smaller pilot study of IgA nephropathy patients, narsoplimab treatment was associated with a roughly 61% reduction in urinary protein excretion during an open-label extension, even in patients with longstanding and advanced disease.²⁵ These early results are encouraging, though both trials were relatively small and regulatory approval has not yet been granted for any indication.

An Immune System Older Than Antibodies

The lectin pathway is not a recent evolutionary invention. Molecular cloning of MASP-like proteases from the Japanese ascidian, a sea squirt that is among our closest invertebrate relatives, revealed that the lectin pathway likely predates both the classical and alternative complement pathways.²⁶ The ascidian proteases turned out to be more closely related to mammalian MASPs than to the enzymes of the classical pathway, suggesting that recognizing foreign sugars with lectins and activating proteases on the spot was the original complement strategy. The classical pathway, which depends on antibodies, came later in evolution along with the adaptive immune system of jawed vertebrates.²⁷

This evolutionary depth helps explain why the lectin pathway is so deeply embedded in host defense. It has been refined over hundreds of millions of years of host-pathogen warfare, and its backup activation routes, its crosstalk with clotting, and its ability to recognize a diverse set of sugar patterns all reflect that long history. It also raises the question of why, given its importance, MBL deficiency is so common in humans, affecting a substantial fraction of the population. One hypothesis is that moderate reductions in MBL confer some benefit against specific infections or inflammatory conditions, maintaining genetic diversity through balancing selection, though this remains debated.